Document is current
Any future updates will be listed below
-
Authors
George, Daniel J. http://orcid.org/0000-0002-0836-8542
Ramaswamy, Krishnan http://orcid.org/0000-0003-0890-0268
Yang, Hongbo
Liu, Qing
Zhang, Adina
Greatsinger, Alexandra
Ivanova, Jasmina http://orcid.org/0000-0002-4028-9676
Thompson, Betty
Emir, Birol
Hong, Agnes
Freedland, Stephen J. http://orcid.org/0000-0002-8104-6419
-
Funding
Funding for this research was provided by:
Astellas Pharma US
Pfizer
Pfizer Inc. | Pfizer UK
- License Information
-
More Information
Article History
Received: 12 September 2023
Revised: 20 February 2024
Accepted: 26 February 2024
First Online: 27 March 2024
Competing interests
: DJG reports being a consultant for Bayer, Exelixis, Pfizer Inc., Sanofi, Astellas Pharma Inc., Innocrin Pharma, Bristol Meyers Squibb, Genentech, Janssen, Merck Sharp & Dohme, Sumitomo Pharma America, Inc. (formerly Myovant Sciences), AstraZeneca, Michael J. Hennessy Associates, Constellation Pharmaceuticals, Physicians’ Education Resource, Propella Therapeutics, RevHealth, Xcures, Novartis, Dendreon, Acerta, and Calithera Biosciences. KR, AH, JI, BT, and EB are employees of Pfizer Inc. HY, QL, AZ, and AG are employees of Analysis Group, which was a paid consultant to Pfizer in connection with the development of this manuscript. SJF reports being a consultant for Astellas Pharma Inc., AstraZeneca, Bayer, Clovis Oncology, Exact Sciences Corporation, Janssen Biotech, Merck, Pfizer Inc., Sanofi, Sumitomo Pharma America, Inc. (formerly Myovant Sciences), and Tempus.
